Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
Hi! Welcome to the last article in the 3-part series on reimbursement. This time, I’m sharing some facts about private health insurance
Hello again, and welcome to the second post in the 3-part series on reimbursement. Last week, we focused on the reimbursement of
Welcome to the start of our 3-part series on reimbursement, starting with reimbursement of drugs in Germany. Today, you will learn about:
Hi, welcome back to the latest article. In the last few weeks, we have learned about how drugs are priced in Germany,